Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

The rate of atrial fibrillation was also higher in RSV patients, although it depended on preexisting heart conditions and ...

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...

Children hospitalized with RSV showed higher risk for ICU admission, IMV, and supplemental oxygen than children hospitalized with COVID-19 or influenza.

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that ...

Modern medicine is largely reactive—treating illness only after symptoms emerge. But a new study from the Research Institute ...